Literature DB >> 16133396

Relative roles of bone scintigraphy and positron emission tomography in assessing the treatment response of bone metastases.

J R García, M Simó, M Soler, G Pérez, S López, F Lomeña.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16133396     DOI： 10.1007/s00259-005-1843-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  11 in total

Review 1.  The role of nuclear medicine in monitoring treatment in skeletal malignancy.

Authors:  G J Cook; I Fogelman
Journal:  Semin Nucl Med       Date:  2001-07       Impact factor: 4.446

2.  Bone scanning. A very useful and commonly performed procedure in evaluation of patients with carcinoma.

Authors:  W J Strader; R J Lull
Journal:  Southwest Med       Date:  1970-11

3.  Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.

Authors:  J E Mortimer; F Dehdashti; B A Siegel; K Trinkaus; J A Katzenellenbogen; M J Welch
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

4.  Changes in 87mSr concentractions in skeletal metastases in patients responding to cyclical combination chemotherapy for advanced breast cancer.

Authors:  P J Gillespie; J L Alexander; G A Edelstyn
Journal:  J Nucl Med       Date:  1975-03       Impact factor: 10.057

Review 5.  Current role of bone scan with phosphonates in the follow-up of breast cancer.

Authors:  Lorenzo Maffioli; Luigia Florimonte; Luca Pagani; Ivana Butti; Isabel Roca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-16       Impact factor: 9.236

Review 6.  Position of nuclear medicine modalities in the diagnostic work-up of breast cancer.

Authors:  J R Buscombe; B Holloway; N Roche; E Bombardieri
Journal:  Q J Nucl Med Mol Imaging       Date:  2004-06       Impact factor: 2.346

7.  Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.

Authors:  Sendhil Kumar Cheran; James E Herndon; Edward F Patz
Journal:  Lung Cancer       Date:  2004-06       Impact factor: 5.705

8.  Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer.

Authors:  S N Yang; J A Liang; F J Lin; C H Kao; C C Lin; C C Lee
Journal:  J Cancer Res Clin Oncol       Date:  2002-04-19       Impact factor: 4.553

9.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.

Authors:  Stephanie E Stafford; Julie R Gralow; Erin K Schubert; Kristine J Rinn; Lisa K Dunnwald; Robert B Livingston; David A Mankoff
Journal:  Acad Radiol       Date:  2002-08       Impact factor: 3.173

10.  Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.

Authors:  C L Vogel; J Schoenfelder; I Shemano; D F Hayes; R A Gams
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544
View more
  2 in total

1.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

2.  [Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging].

Authors:  A Heidenreich; S Krege
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.